Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study

Harbinger Health, a biotechnology company pioneering the detection of early cancer, and SCRI announced the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger’s novel platform technology for blood-based early cancer detection.